What is Pacira BioSciences, Inc.'s market cap?

Pacira BioSciences, Inc. (PCRX) has a market capitalization of $1.0B and trades on NASDAQ.

What is Pacira BioSciences, Inc.'s revenue and profitability?

Pacira BioSciences, Inc. generated $734.9M in trailing twelve-month revenue with net income of $5.1M, representing a net margin of 0.7%. Gross margin stands at 79.3%, with free cash flow of $132.7M. These figures are based on the Q1 2026 filing.

Who are Pacira BioSciences, Inc.'s competitors?

Pacira BioSciences, Inc.'s key competitors include Heron Therapeutics, Inc., Avanos Medical, Inc., Anika Therapeutics Inc, and others. These companies compete in similar markets and product categories.

Who does Pacira BioSciences, Inc. partner with?

Pacira BioSciences, Inc.'s notable partners include Johnson & Johnson MedTech, LG Chem, Ltd., Thermo Fisher Scientific Pharma Services, and others.

What subsidiaries does Pacira BioSciences, Inc. have?

Pacira BioSciences, Inc.'s subsidiaries include Pacira Pharmaceuticals, Inc., MyoScience, Inc., Flexion Therapeutics, Inc., and others.

Where is Pacira BioSciences, Inc. headquartered?

Pacira BioSciences, Inc. is headquartered in United States of America and employs approximately 712 people. It has been publicly traded since 2011.

Pacira BioSciences, Inc.

PCRX

Pacira BioSciences is a biopharmaceutical company focused on the development and commercialization of innovative, non-opioid pain therapies.

Market cap

$1.04B+3.3%

Revenue$734.9M+4.6%

Net income$5.1M+105%

Free cash flow$132.7M-16.8%

EPS (diluted)$0.12+105%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

April 30, 2026

Revenue$177.4MBeat by $5.6M EPS$0.60Miss by $0.01

Read the full report

Next report

Aug 4, 2026 (In 6 days)

Revenue estimate$191.1M

EPS estimate$0.64

Financials

Q1 2026

Income statement

See full

Revenue$177.4M+5.0%

Gross profit$141.0M+4.7%

Operating income$6.9M+247%

Net income$2.9M-39.4%

EPS (diluted)$0.07-30.0%

Balance sheet

See full

Cash & equivalents$144.3M-49.1%

Total debt$411.2M+15.3%

Total equity$653.9M-18.1%

Total assets$1.2B-23.8%

Cash flow

See full

Operating cash flow$25.7M-27.6%

CapEx$2.7M-68.1%

Free cash flow$23.0M-14.7%

Valuation & ratios

Valuation

See full

Market cap$1.04B+3.3%

Enterprise value$1.31B+22.1%

P/E202.7×—

P/S1.4×0.0×

Profitability

See full

Gross margin79.3%+1.7pp

Operating margin3.3%—

Net margin0.7%—

FCF margin18.1%-4.6pp

Returns & leverage

See full

Return on equity0.7%—

Debt / equity0.6×+0.2×

Current ratio4.7×+2.3×

Segments

By product

See full

EXPAREL$143.3M+4.9%

ZILRETTA$26.8M+14.7%

iovera°$6.2M+20.6%

Bupivacaine liposome injectable suspension$1.2M-55.5%

By segment

See full

Reportable Segment$177.4M+5.0%

Competitors

By market cap

AtriCure$1.9B+15.1%

Collegium Pharmaceutical, Inc.$1.2B+14.3%

Pacira BioSciences, Inc.$1.0B+2.0%

Anika Therapeutics$199.9M+23.0%

Heron Therapeutics$86.9M-69.4%

By revenue growth

Anika Therapeutics+29.5%

Collegium Pharmaceutical, Inc.+19.9%

AtriCure+13.9%

Pacira BioSciences, Inc.+4.6%

By net margin

Collegium Pharmaceutical, Inc.9.41%+2.8pp

Pacira BioSciences, Inc.0.699%+16.5pp

Anika Therapeutics-3.38%+61.7pp

AtriCure-5.55%+8.1pp

Profile

Pacira BioSciences is a biopharmaceutical company focused on the development and commercialization of innovative, non-opioid pain therapies. The company's core value proposition centers on transforming postsurgical and musculoskeletal pain management through long-acting treatments that reduce reliance on opioids. Its portfolio includes proprietary drug delivery technologies and medical devices designed to improve patient outcomes and facilitate the migration of surgeries to outpatient settings.

Competitive position

A leading provider of non-opioid pain management solutions with a dominant position in long-acting local anesthetics and a growing presence in gene therapy for osteoarthritis.

GeographiesUnited States, European Union, United Kingdom, Asia-Pacific

Customer segmentsHealthcare Providers, Hospitals, Ambulatory Surgical Centers

Business modelProduct Manufacturing, Research and Development, Licensing

SuppliersRaw material suppliers, Contract manufacturing organizations, Specialized equipment manufacturers

CustomersPharmaceutical wholesalers, Hospitals, Ambulatory surgical centers, Specialty physician practices

CountryUnited States of America

Listed2011

Employees712.0

CEOFrank D. Lee

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

Websitepacira.com

FilingsSEC EDGAR

Ask your AI about Pacira BioSciences, Inc..

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Pacira BioSciences, Inc.'s market cap?: Pacira BioSciences, Inc. (PCRX) has a market capitalization of $1.0B and trades on NASDAQ.
What is Pacira BioSciences, Inc.'s revenue and profitability?: Pacira BioSciences, Inc. generated $734.9M in trailing twelve-month revenue with net income of $5.1M, representing a net margin of 0.7%. Gross margin stands at 79.3%, with free cash flow of $132.7M. These figures are based on the Q1 2026 filing.
Who are Pacira BioSciences, Inc.'s competitors?: Pacira BioSciences, Inc.'s key competitors include Heron Therapeutics, Inc., Avanos Medical, Inc., Anika Therapeutics Inc, and others. These companies compete in similar markets and product categories.
Who does Pacira BioSciences, Inc. partner with?: Pacira BioSciences, Inc.'s notable partners include Johnson & Johnson MedTech, LG Chem, Ltd., Thermo Fisher Scientific Pharma Services, and others.
What subsidiaries does Pacira BioSciences, Inc. have?: Pacira BioSciences, Inc.'s subsidiaries include Pacira Pharmaceuticals, Inc., MyoScience, Inc., Flexion Therapeutics, Inc., and others.
Where is Pacira BioSciences, Inc. headquartered?: Pacira BioSciences, Inc. is headquartered in United States of America and employs approximately 712 people. It has been publicly traded since 2011.